Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01505153 | Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer(STMN1-LP) | completed | Phase 1 | 20 | Gradalis, Inc.INDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | terminated | Phase 1 | 42 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00139620 | A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function | completed | Phase 1 | 39 | OSI PharmaceuticalsINDUSTRY | 2 | Feb 8, 2018 | clinicaltrials |
| NCT00095862 | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | terminated | Phase 1 / Phase 2 | 24 | Wiseman Research Initiatives LLCINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01668550 | A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours(AZD0424) | terminated | Phase 1 | 43 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02228811 | A Study of DCC-2701 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 44 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01519817 | Cancer Vaccine Targeting Brachyury Protein in Tumors | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2018 | clinicaltrials |
| NCT02318394 | A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2018 | clinicaltrials |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | terminated | Phase 1 | 5 | Incyte CorporationINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT03398720 | Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00033241 | Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors | completed | Phase 1 | — | OSI PharmaceuticalsINDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00470548 | Abraxane and Alimta in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00807755 | Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors | terminated | Phase 1 | 5 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01336842 | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | completed | Phase 1 | 23 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02194049 | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | completed | Phase 1 | 3 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01987362 | A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2018 | clinicaltrials |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT00921869 | A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00098514 | Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03313219 | Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China | unknown | Phase 1 | 20 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02940132 | A Study of SC10914 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00622674 | Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01072266 | A Dose-escalation Study in Subjects With Advanced Malignancies | completed | Phase 1 | 45 | Incyte CorporationINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00718380 | A Phase 1 Study of ABT-869 in Subjects With Solid Tumors | completed | Phase 1 | 18 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00733187 | Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 | completed | Phase 1 | 34 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00887757 | Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors | completed | Phase 1 | 46 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00891605 | Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | completed | Phase 1 | 19 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00982566 | Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer | completed | Phase 1 | 37 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01121133 | A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax | completed | Phase 1 | 12 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01199224 | To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 27 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01255657 | A Study of ABT-806 in Subjects With Advanced Solid Tumor Types | completed | Phase 1 | 49 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01413893 | An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01472016 | Study of ABT-700 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 74 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01009073 | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects | completed | Phase 1 | 51 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01617928 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | completed | Phase 1 | 12 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02593708 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | terminated | Phase 1 | 6 | Michelle MeliskoOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | completed | Phase 1 | 38 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00483860 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | completed | Phase 1 | 59 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT00687622 | Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | completed | Phase 1 | 206 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00732420 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | completed | Phase 1 | 68 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT01324258 | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | completed | Phase 1 | 19 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00389584 | Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors | completed | Phase 1 / Phase 2 | 30 | University of California, DavisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01331941 | A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function | completed | Phase 1 | 35 | AmgenINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Feb 22, 2018source: clinicaltrials